Understanding and Exploiting Tunicamycin (Bio)Synthesis to Enable Novel Antibiotics and Inhibitors
Understanding and Exploiting Tunicamycin (Bio)Synthesis to Enable Novel Antibiotics and Inhibitors
批准号:
BB/J009725/1
负责人:
Benjamin Davis
金额:
$60.47万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2012
资助国家:
英国
项目状态:
已结题
起止时间:
2012 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Streptomyces are bacteria that live in the soil and produce antibiotics to compete with other soil microorganisms. Tunicamycin is an antibiotic made by Streptomyces chartreusis with a very unusual chemical structure. It kills other bacteria by blocking the action of a protein (an enzyme) that performs an essential role in making the walls of bacterial cells. These cell walls are essential for bacteria to survive. The way in which tunicamycin kills bacteria is different to almost all other antibiotics that are used in medicine and so tunicamycin has the potential to become a new and very effective antibacterial treatment to counter, for example, MRSA infections.The chemical structure of tunicamycin is actually similar to some of the building blocks used to make cell walls. This suggests that it may act my mimicking these building blocks, preventing the enzyme that makes cell walls from choosing the correct components. We have discovered recently the genes that allow S. chartreusis to make tunicamycin, and we can now use these genes to produce the enzymes that make tunicamycin. We have also developed methods to make the building blocks, and slightly different versions of them, that are used to make tunicamycin. As a consequence, we are now in a very good position to understand not only how the very unusual tunicamycin structure is made by S. chartreusis, but also to use the enzymes and the variant building blocks to generate new tunicamycin-like compounds. Ultimately we aim to genetically manipulate S. chartreusis itself to produce such compounds. Why is this important? Although tunicamycin is very good at killing bacteria, it also harms human cells, and so cannot be used as an antibiotic. By changing the structure of tunicamycin, we hope to remove the activity that is deleterious to humans, while retaining, or even improving, the activity against bacteria.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1038/nchem.1695
发表时间:
2013-08
期刊:
Nature chemistry
影响因子:
21.8
作者:
[Lingbing Kong;Leon Harrington;Qiuhong Li;S. Cheley;B. G. Davis;H. Bayley]
通讯作者:
Lingbing Kong;Leon Harrington;Qiuhong Li;S. Cheley;B. G. Davis;H. Bayley
DOI:
10.1128/aac.00130-18
发表时间:
2018-08
期刊:
Antimicrobial agents and chemotherapy
影响因子:
4.9
作者:
[Widdick D, Royer SF, Wang H, Vior NM, Gomez-Escribano JP, Davis BG, Bibb MJ]
通讯作者:
Bibb MJ
Structures of DPAGT1 explain glycosylation disease mechanisms and advance TB antibiotic design
DPAGT1 的结构解释了糖基化疾病机制并推进结核病抗生素设计
DOI:
10.1101/291278
发表时间:
2018
期刊:
影响因子:
--
作者:
[Dong Y]
通讯作者:
Dong Y
Sugars and proteins
糖和蛋白质
DOI:
--
发表时间:
2012
期刊:
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY
影响因子:
--
作者:
[Davis Ben]
通讯作者:
Davis Ben
Refocussing Antibody Responses by Chemical Modification of Vaccine Antigens
通过疫苗抗原的化学修饰重新聚焦抗体反应
DOI:
--
发表时间:
2014
期刊:
AIDS RESEARCH AND HUMAN RETROVIRUSES
影响因子:
1.5
作者:
[Schiffner Torben]
通讯作者:
Schiffner Torben
共 7 条
ISOBIOTICS: Isotopic Labeling of Biotherapeutics
-
批准号:EP/X039501/1
-
项目类别:Research Grant
-
资助金额:$33.8万
-
财政年份:2023
-
负责人:Benjamin Davis
-
依托单位:
Exploring and Driving Cooperative International Strategies in Sustainable Chiral Pool Natural Product Synthesis
-
批准号:BB/W018705/1
-
项目类别:Research Grant
-
资助金额:$4.42万
-
财政年份:2022
-
负责人:Benjamin Davis
-
依托单位:
Radical Radiochemistry for Site- and Copy-Controlled 18F-Labeling of Proteins
-
批准号:BB/V010999/1
-
项目类别:Research Grant
-
资助金额:$107.73万
-
财政年份:2021
-
负责人:Benjamin Davis
-
依托单位:
Rosalind Franklin Institute - Next Generation Chemistry
-
批准号:EP/V011359/1
-
项目类别:Research Grant
-
资助金额:$474.38万
-
财政年份:2020
-
负责人:Benjamin Davis
-
依托单位:
Understanding a Mutant that Disregulates Trehalose 6-Phosphate Action in Plants
-
批准号:BB/T016329/1
-
项目类别:Research Grant
-
资助金额:$101.75万
-
财政年份:2020
-
负责人:Benjamin Davis
-
依托单位:
A High-throughput discovery facility for the Rosalind Franklin Institute
-
批准号:EP/V011367/1
-
项目类别:Research Grant
-
资助金额:$257.64万
-
财政年份:2020
-
负责人:Benjamin Davis
-
依托单位:
Engineering stable calibration standards for biomedical research
-
批准号:EP/I500200/1
-
项目类别:Research Grant
-
资助金额:$12.95万
-
财政年份:2011
-
负责人:Benjamin Davis
-
依托单位:
The CHELL : A Bottom-Up approach to in vitro and in silico Minimal Life-like Constructs
-
批准号:EP/G026688/1
-
项目类别:Research Grant
-
资助金额:$73.14万
-
财政年份:2009
-
负责人:Benjamin Davis
-
依托单位:
Creating a Synthetic Platform for Understanding and Exploiting Glycoconjugates
-
批准号:EP/E000614/1
-
项目类别:Research Grant
-
资助金额:$82.3万
-
财政年份:2007
-
负责人:Benjamin Davis
-
依托单位:
Dissecting the mechanism by which glycosyltransferases calalyse mannosyl transfer
-
批准号:BB/E004350/1
-
项目类别:Research Grant
-
资助金额:$49.38万
-
财政年份:2007
-
负责人:Benjamin Davis
-
依托单位:
海外基金